Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES SUN PHARMA ALKEM LABORATORIES/
SUN PHARMA
 
P/E (TTM) x 25.0 140.2 17.8% View Chart
P/BV x 6.0 3.2 187.5% View Chart
Dividend Yield % 0.8 0.7 121.7%  

Financials

 ALKEM LABORATORIES   SUN PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
SUN PHARMA
Mar-20
ALKEM LABORATORIES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs2,720484 561.9%   
Low Rs1,660315 526.8%   
Sales per share (Unadj.) Rs697.9136.9 509.9%  
Earnings per share (Unadj.) Rs96.117.5 550.8%  
Cash flow per share (Unadj.) Rs117.326.0 450.9%  
Dividends per share (Unadj.) Rs25.004.00 625.0%  
Dividend yield (eoy) %1.11.0 114.0%  
Book value per share (Unadj.) Rs515.2188.7 273.1%  
Shares outstanding (eoy) m119.572,399.26 5.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.12.9 107.5%   
Avg P/E ratio x22.822.9 99.5%  
P/CF ratio (eoy) x18.715.4 121.5%  
Price / Book Value ratio x4.32.1 200.7%  
Dividend payout %26.022.9 113.5%   
Avg Mkt Cap Rs m261,879958,864 27.3%   
No. of employees `00014.317.8 80.7%   
Total wages/salary Rs m15,05563,624 23.7%   
Avg. sales/employee Rs Th5,822.618,490.6 31.5%   
Avg. wages/employee Rs Th1,050.53,582.6 29.3%   
Avg. net profit/employee Rs Th802.02,357.6 34.0%   
INCOME DATA
Net Sales Rs m83,444328,375 25.4%  
Other income Rs m1,0426,360 16.4%   
Total revenues Rs m84,486334,735 25.2%   
Gross profit Rs m14,73469,898 21.1%  
Depreciation Rs m2,52820,528 12.3%   
Interest Rs m6513,027 21.5%   
Profit before tax Rs m12,59852,702 23.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,606 0.0%   
Tax Rs m1,1058,228 13.4%   
Profit after tax Rs m11,49341,868 27.5%  
Gross profit margin %17.721.3 83.0%  
Effective tax rate %8.815.6 56.2%   
Net profit margin %13.812.8 108.0%  
BALANCE SHEET DATA
Current assets Rs m54,960316,542 17.4%   
Current liabilities Rs m32,433157,064 20.6%   
Net working cap to sales %27.048.6 55.6%  
Current ratio x1.72.0 84.1%  
Inventory Days Days8088 90.9%  
Debtors Days Days72105 68.9%  
Net fixed assets Rs m32,710243,102 13.5%   
Share capital Rs m2392,399 10.0%   
"Free" reserves Rs m61,368450,245 13.6%   
Net worth Rs m61,607452,645 13.6%   
Long term debt Rs m1,59220,289 7.8%   
Total assets Rs m99,433682,525 14.6%  
Interest coverage x20.418.4 110.6%   
Debt to equity ratio x00 57.7%  
Sales to assets ratio x0.80.5 174.4%   
Return on assets %12.26.6 185.7%  
Return on equity %18.79.2 201.7%  
Return on capital %21.011.2 186.6%  
Exports to sales %19.10-   
Imports to sales %3.00-   
Exports (fob) Rs m15,917NA-   
Imports (cif) Rs m2,483NA-   
Fx inflow Rs m16,06174,219 21.6%   
Fx outflow Rs m2,48327,964 8.9%   
Net fx Rs m13,57846,255 29.4%   
CASH FLOW
From Operations Rs m5,85165,548 8.9%  
From Investments Rs m-7,414-25,888 28.6%  
From Financial Activity Rs m792-57,151 -1.4%  
Net Cashflow Rs m-731-13,857 5.3%  

Share Holding

Indian Promoters % 66.9 63.7 105.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 5.1 645.2%  
FIIs % 0.0 23.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 8.3 -  
Shareholders   68,381 133,026 51.4%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  UNICHEM LAB  ALEMBIC PHARMA  ELDER PHARMA  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex and Nifty Fell Over 1% Today(Closing)

Indian share markets witnessed heavy selling pressure today, pausing the record rally, with all sectors barring telecom, reeling under pressure.

Related Views on News

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Five Wishes and a Will(The Honest Truth)

Jan 4, 2021

Ajit Dayal on the investing strategy for 2021 and beyond.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jan 15, 2021 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS